Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25554707 | 0.80 | LMNA (0.33) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL25554534 | 0.80 | LMNA (0.33) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL25554252 | 0.80 | LMNA (0.33) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL25554980 | 0.78 | LMNA (0.32) | LMNACNR1ADRA1ATDP1KDM4E | |
| SCHEMBL25554489 | 0.76 | KMT2A (0.41) | ADRA1AKDM4ESMN1; SMN2 | |
| SCHEMBL25554258 | 0.76 | KDM4E (0.34) | KDM4E | |
| SCHEMBL25554569 | 0.76 | KMT2A (0.41) | ADRA1AKDM4ESMN1; SMN2 | |
| SCHEMBL22385121 | 0.75 | — | — | |
| SCHEMBL19836686 | 0.75 | ADH1B (0.36) | — | |
| SCHEMBL4746164 | 0.74 | LMNA (0.32) | LMNATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159532-A1 | PARATHYROID HORMONE (PTH) RECEPTOR ANTAGONISTS AND USES THEREOF | PTH1R, CALCR, VDR | LMNA 1955/4885CNR1 788/4885ADRA1A 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.